The Integration Session

What are the biggest gaps between psychedelic trials and what actually happens in the dosing room? And how might an Ayahuasca-inspired drug formulation affect shame and self-referential thinking? In this episode, we are joined by Dr. Helena Aicher, a research associate at the University of Zurich and Basel, where she is involved in clinical trials investigating psychedelic interventions. Alongside...

Therapeutic touch is often used in psychedelic therapy, but what ethical guidelines and boundaries should researchers and therapists follow? What can we learn from patient perspectives about consent, and where to draw the line? In this episode, Dr. Rachel Ham joins us from Monash University in Melbourne, Australia to discuss two companion studies from her research group: one capturing experiences...

Psychedelics are often described as capable of “rewiring the brain,” but this leaves out a more complex and elegant series of mechanisms beneath the cortex. This episode goes a layer deeper to explore specific brain regions and receptors that are less often talked about in psychedelic science, despite their critical role in psychedelic drug action. Dr. Tanner Anderson, a postdoctoral neuroscientis...

What does it actually mean, physically, for a brain to be conscious, and what can psychedelics teach us about it? Can consciousness extend beyond living things, including artificial intelligence? In this episode of The Integration Session, we're joined by Dr. Adam Barrett, Associate Professor in Machine Learning and Data Science and Deputy Director of the Sussex Centre for Consciousness Scienc...

What can two decades of clinical research teach us about psilocybin's potential for treating obsessive-compulsive disorder (OCD)? In this episode, we sit down with Dr. Francisco Moreno, a pioneer in psychedelic-assisted treatment research, to trace the arc of his work - from his landmark 2006 trial, one of the first modern investigations of psilocybin for OCD, to his newly published 2026 rando...

Want to stay updated on the latest advancements in psychedelic science without reading lengthy scientific papers? Welcome back to Research Recap, where Elena breaks down three recent studies in psychedelic science, in a digestible format. This episode covers a phase IIa trial of short-acting intravenous DMT for depression, a multimodal neuroimaging study of a first psilocybin experience, and an in...

Psychedelic treatments are often celebrated for their antidepressant potential, but emerging research suggests their effects go beyond traditional mood improvement. These compounds appear to work on multiple levels, prompting researchers to propose a more accurate term: “anti distressant .”  But what exactly does “antidistressant” mean, and how might it better reflect the broad effects of psychede...

Psychedelics and psychosis have long been intertwined. Historically, psychedelics were more often called ‘psychotomimetics’ or compounds that temporarily mimic the symptoms of psychosis. But today, rather than modelling psychopathology, psychedelics are more often viewed as therapeutic tools in psychiatry. But this creates a paradox in modern psychedelic science: psychedelics are being studied bot...

One of the most talked-about psychedelics in recent years is ibogaine, especially amidst recent policy shifts that aim to fast-track research progress in this area. While early evidence shows therapeutic potential for opioid addiction and PTSD in veterans, legitimate concerns remain regarding safety and cardiac risks. So, what does the clinical data really show about ibogaine’s therapeutic benefit...

One of the most pressing challenges in psychedelic science is the placebo problem: the intense subjective effects of psychedelics cause functional unblinding and amplify expectancy effects, undermining the integrity of gold-standard randomized controlled trials. In this episode of The Integration Session, we are joined by Dr. Balázs Szigeti, clinical data scientist at the UCSF Translational Psyche...

Diane Gratton—a retired nurse, educator, and grandmother—was diagnosed with stage 4 breast cancer with bone metastases in 2021, with an initial prognosis of five years. In this episode, she opens up about her journey with psychedelic therapy: her motivations, fears, how she prepared, her two psilocybin experiences (individual and group), and the profound emotional and existential insights that fol...

From the hippie counterculture vibes of the 1960s to the haunting visions of Midsommar, or the optimism of How to Change Your Mind, psychedelics have long shaped (and been shaped by) popular media. But how do these portrayals reflect and influence cultural narratives around altered states, spirituality, and transformation? And in what ways do they borrow from, distort, or reinvent the language of...

Although the therapeutic promise of psychedelics is often highlighted, there is a much larger story at play here: one of corporate power, political ideology, digital surveillance, and fundamental questions about the limits of Western medicine. In this episode of The Integration Session, we step back from treatment breakthroughs to examine the bigger story: the rapid rise of ‘Psychedelic Capitalism...

Humans have always needed community to heal, grow, and make meaning in this life - something Indigenous and traditional healing practices have long incorporated alongside psychedelic medicine. Yet Western cultures, steeped in individualism, seem to be only recently rediscovering the importance of community. So, what should the true role of community be in psychedelic integration? More broadly, how...

Demoralization syndrome affects a substantial portion of patients with advanced cancer, but how does it differ from depression? How might psilocybin help patients find relief and peace while facing their own mortality? In this episode, Dr. Carolina Hernandorena, psychiatrist and PhD candidate in neuroscience at Queen’s University, shares her journey from psychiatric training in Argentina to psyche...

What can we learn from psychedelic use in people with lived experience of eating disorders? As a population with barely any approved medications, surprising self-reports reveal that cannabis and psychedelics may offer high rates of real-world symptom relief. In this episode of The Integration Session, we are joined by Sarah Rodan, a postdoctoral research associate at the InsideOut Institute in Syd...

Women’s bodies have long been treated as a ‘variable’ to control for in science, rather than a focus of research inquiry. Psychedelic science is no exception, with major knowledge gaps regarding the menstrual cycle, menopause, and pregnancy. But, what might be discovered if we become more curious about women’s physiology in psychedelic science? In this episode, we are joined by Dr. Grace Blest-Hop...

Join Dr. Bia Labate, anthropologist, activist, and Executive Director of the Chacruna Institute for Psychedelic Plant Medicines, in this live interview brought to you by the Queen’s University Psychedelic Society Speaker Series. With over 30 years of global experience in psychedelic traditions, Dr. Labate shares the motivations behind her lifelong commitment to plant medicines and social justice....

From Johns Hopkins to Ottawa, Dr. Jérémie Richard is a clinical psychologist with unique binational experience in the field of psychedelic science. Now an Assistant Professor at the University of Ottawa and director of the Clinical & Applied Psychedelic Science Lab, Dr. Richard joins host Dr. Elena Koning to trace his career path and share his most personally impactful and ongoing work in psyc...

Psychedelics are increasingly recognized as an approach to help heal trauma – but without the proper support, the same experience that enables healing could lead to re-traumatization. How does this work and what should psychedelic therapists do about it? Guy Simon is a clinical social worker, psychotherapist, and PhD candidate experienced in trauma-informed psychedelic therapy. Guy’s recent work t...

How does one pivot from running a successful construction business in India to becoming a leading voice in psychedelic advocacy and mental health in Canada?  In this episode of The Integration Session, host Elena is joined by Osheen Dayal–a University of British Columbia Psychology alumna, former co-president of the Women Empowerment Club, and current Master’s student in Counselling Psychology at...

2025 was a pivotal year for psychedelic research at the Centre for Psychedelics Health & Research (CPHR) and across Canada. In this year-end finale of The Integration Session, host Dr. Elena Koning sits down with CPHR Director Dr. Claudio Soares for a reflective conversation on progress, breakthroughs, and the road ahead.  Dr. Soares shares his professional journey in psychiatry, the evolution...

Chronic pain impacts over 1.5 billion people worldwide, with the majority of affected individuals being women. As conventional treatments don’t always help, there’s an emerging interest in the potential of psychedelic therapies. In this episode of The Integration Session, we explore the current state of the science on psychedelics as an approach to alleviating pain and improving quality of life in...

Have you ever wondered what it’s like to sit with someone having one of the most profound experiences of their life? In this deeply candid conversation, psychedelic therapist Denise Rue brings a wealth of experience to our discussion about facilitating psychedelic therapy. We discuss her journey to the field, the nuances of guiding individuals through psychedelic therapy, the surprising ways clini...

Which psychedelic therapy is the most cost-effective? How can we determine the value of a psychedelic treatment? In this episode of The Integration Session, we discuss the crucial economic landscape of psychedelic therapies with Dr. Elliot Marseille, a health economist and founding director of the Collaborative for the Economics of Psychedelics at UC Berkeley and UC San Francisco. As a leading exp...